Online education needs and preferences of patients with cancer and their caregivers.

e21669 Background: Patients and caregivers have many questions upon receiving a diagnosis of cancer. One way to help alleviate this burden, and enable participation in care is through education. Patient education correlates with higher levels of satisfaction and improved clinical outcomes. However, little is known about how patients and caregivers define their education needs. Methods: We surveyed patients with cancer and caregivers to assess their perceived education needs and resources. Results:2327 individuals representing 9 malignancies participated in the survey. Participants were predominantly patients (72%), with a majority (51%) having received their initial diagnosis of cancer within the past 2 years. Less than a quarter (22%) of respondents felt their educational needs were being completely met by available resources. Respondents were most likely to seek out information at the time of diagnosis (24%) and to increase understanding of treatment options (24%). Conversely, individuals were least likely to seek education upon disease progression (7%). In all malignancies examined, the 2 topics considered most important were treatment options (70%-89%) and understanding test results (74%-87%) while information about how to take medication as prescribed was deemed least important (46%-67%). Conclusions: Our study identified a lack of educational materials available and designed to meet cancer patients’ needs on the internet. Given that few patients and caregivers reported that their educational needs are being met, efforts may be needed to ensure that those patients who want to receive education to become informed patients can find what they need, when they need it.

Download Full-text

COT-13 Current situation and problems of cancer genomic profiling test in Kyoto University Hospital

Neuro-Oncology Advances ◽

10.1093/noajnl/vdaa143.099 ◽

2020 ◽

Vol 2 (Supplement_3) ◽

pp. ii22-ii22

Author(s):

Yoshiki Arakawa ◽

Junko Suga ◽

Yukinori Terada ◽

Kohei Nakajima ◽

Masahiro Tanji ◽

...

Keyword(s):

Treatment Options ◽

Insurance Coverage ◽

Germline Mutations ◽

University Hospital ◽

Genomic Profiling ◽

Test Results ◽

Final Test ◽

First Time ◽

To Receive ◽

Secondary Finding

Abstract Objective: Kyoto University Hospital has introduced the cancer genomic profiling tests, Oncoprime in 2015, Guardant360 in 2018, which are not under insurance coverage, FoundationOne CDx(F1CDx) and OncoGuide NCC Oncopanel system(NCC OP) in 2019, which received approval for insurance coverage for the first time in Japan. We investigated the results of cancer genomic profiling test under insurance coverage in our hospital. Methods: A special facility for the cancer genomic profiling tests was produced. To perform the cancer genomic profiling test, an outpatient must visit the facility three times (learning, ordering of the test, and getting the results). The expert panels decide the final test results and treatment options with the all information of the patients. Results: From November 2019 to March 2020, 51 and 9 patients were tested with F1CDx and NCC OP, respectively. 16 patients (31%) of F1CDX and 2 patients (22%) of NCC OP got treatment recommendations from the expert panels. However, only 5 patients (9.8%) of F1CDX and 1 patient (11%) of NCC OP received the treatments. The secondary finding suspecting germline mutations was found in 8 patients of F1CDX. Conclusion: After the approval the cancer genomic profiling tests with insurance coverage in Japan, it becomes easy for the patients to perform the test and get the genetic information of the tumor. However, it remains not easy to receive the recommended drugs because of several limitations of their usages.

Download Full-text

Treatment center (TC) variability in survival of patients (pts) with colorectal cancer (mCRC) treated with bevacizumab (BV): A subanalysis from the BRiTE Observational Study (OCS)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e17532 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e17532-e17532

Author(s):

H. V. Barron ◽

D. M. Purdie ◽

S. Feng ◽

A. P. Sing

Keyword(s):

Treatment Options ◽

Treatment Center ◽

Proportional Hazard ◽

Proportional Hazard Model ◽

Contributing Factors ◽

First Line ◽

Site Factors ◽

The Past ◽

Cox Proportional Hazard ◽

To Receive

e17532 Background: Treatment options and overall survival (OS) rates for pts with mCRC have increased markedly over the past decade. However, the variability in OS across TCs, and possible contributing factors (measured and unmeasured), remain unclear. We present an analysis from the BRiTE OCS assessing variability in OS as a function of TC, and sought to identify site factors that may predict better outcomes. Methods: BRiTE enrolled 1,953 pts with mCRC receiving a first-line BV-based regimen, from 248 U.S. sites, mostly community practices (Grothey et al. J Clin Oncol. 2008 26:5326). A Cox proportional hazard model was used to identify predictors of OS (age, PS, albumin, alkaline phosphatase, site of primary tumor) and calculate the expected number of deaths (E) compared to the observed number of deaths (O) within each TC. The ratio O/E was calculated and its distribution is presented. Sites with high O/E (top 25%) vs low O/E (lowest 25%) were titled “worst” (W) and “best” (B), respectively. B and W sites were compared by type (academic vs community, hospital vs clinic, urban vs rural), number of pts treated, choice of first-line chemotherapy, postprogression (PD) therapy, and duration of BV. TCs with ≥3 pts were included in the analysis (198). Results: Significant variation in the O/E ratio was observed across TCs ( Table ). The differences between W and B TCs were that pts at W TCs were less likely to receive a first-line oxali containing regimen (65% vs 67%), had shorter overall duration of BV (8 m vs 12 m) and were less likely to use BV following PD (33% vs 39%). Measured site, pt, and treatment variables explained ∼7% of the variability in O/E, suggesting most TC variability was due to unmeasured factors. Conclusions: Significant variability in OS exists across BRiTE TCs, which appears partly related to the specific therapies received by pts. Further work is needed to determine whether W TCs can be optimized and improve outcomes in pts with mCRC. [Table: see text] [Table: see text]

Download Full-text

Oncology Clinical Trials During the COVID-19 Pandemic

ONCOLOGY ◽

10.46883/onc.2020.3407.0265 ◽

2020 ◽

pp. 265-269

Author(s):

Aline Lara Gongora ◽

Denis Jardim ◽

Diogo Assed Bastos

Keyword(s):

Clinical Trials ◽

Mortality Rates ◽

Research Community ◽

Regulatory Agencies ◽

Patients With Cancer ◽

The Past ◽

Oncology Research ◽

Oncology Clinical Trials ◽

National Governments ◽

To Receive

The coronavirus disease 2019 (COVID-19) pandemic has rapidly spread all over the world in the past several months. No effective treatment for COVID-19 has been established. High transmissibility and considerable mortality rates have forced many national governments to implement quarantine measures. Many patients with cancer rely on clinical trials to receive their oncologic care, but the routine conduct of clinical trials has substantially changed because of the COVID-19 pandemic. The oncology research community should implement formal policies based on the guidance given from regulatory agencies, with the goal of minimizing the risks of COVID-19 infection while maintaining appropriate oncologic treatments for patients during this pandemic.

Download Full-text

Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants

Hematology ◽

10.1182/asheducation-2010.1.144 ◽

2010 ◽

Vol 2010 (1) ◽

pp. 144-149 ◽

Cited By ~ 37

Author(s):

Agnes Y.Y. Lee

Keyword(s):

Treatment Options ◽

Low Molecular Weight ◽

Ongoing Research ◽

Patients With Cancer ◽

Cancer Management ◽

The Past ◽

Risk Assessment Models ◽

Improved Outcomes ◽

Risk Patients ◽

Clinical Questions

Abstract Thromboembolism is a common, complex, and costly complication in patients with cancer. Management has changed significantly in the past decade, but remains firmly dependent on the use of anticoagulants. Low-molecular-weight heparin is the preferred anticoagulant for prevention and treatment, although its limitations open opportunities for newer oral antithrombotic agents to further simplify therapy. Multiple clinical questions remain, and research is focusing on identifying high-risk patients who might benefit from primary thromboprophylaxis, treatment options for those with established or recurrent thrombosis, and the potential antineoplastic effects of anticoagulants. Risk-assessment models, targeted prophylaxis, anticoagulant dose escalation for treatment, and ongoing research studying the interaction of coagulation activation in malignancy may offer improved outcomes for oncology patients.

Download Full-text

Rationale for heparin treatment of colon cancer

Hämostaseologie ◽

10.1055/s-0037-1619481 ◽

2000 ◽

Vol 20 (03) ◽

pp. 136-142 ◽

Cited By ~ 2

Author(s):

D. L. Ornstein ◽

L. R. Zacharski

Keyword(s):

Clinical Trials ◽

Substantial Improvement ◽

Patients With Cancer ◽

Coagulation Mechanism ◽

Anticoagulant Drug ◽

Cancer Outcome ◽

Meta Analyses ◽

Improvement In Survival ◽

Spectrum Of Patients ◽

To Receive

SummaryIt is widely known that the systemic blood coagulation mechanism is often activated in malignancy, leading to an increased incidence of vascular thromboses in patients with cancer. It is not widely appreciated, however, that products of the coagulation mechanism may also support tumor growth and dissemination. Interest in this approach to cancer therapy has surged recently because of mounting evidence that the familiar anticoagulant drug, heparin, may impede tumor progression. Heparin has the capacity to modify angiogenesis, growth factor and protease activity, immune function, cell proliferation and gene expression in ways that may block malignant dissemination. Clinical trials in which heparin has been administered to a broad spectrum of patients to prevent or treat thrombosis have unexpectedly shown improvement in survival in the subset of patients with malignancy entered to these studies. Meta-analyses of clinical trials comparing unfractionated (UF) versus low molecular weight (LMW) heparin treating venous thromboembolism suggest that there may be substantial improvement in cancer outcome in patients with malignancy randomized to receive LMW heparin. These findings provide a rationale for definitive clinical trials of LMW heparin in cancer, and the results of several such studies that are currently underway are awaited with interest.

Download Full-text

Endovenous procedures in varicose veins

Phlebologie ◽

10.1055/s-0037-1622235 ◽

2008 ◽

Vol 37 (05) ◽

pp. 229-236

Author(s):

N. Cayne ◽

G. Jacobowitz ◽

P. Lamparello ◽

T. Maldonado ◽

C. Rockman ◽

...

Keyword(s):

Varicose Veins ◽

Treatment Options ◽

Postoperative Recovery ◽

Comparable Efficacy ◽

Intense Pulse Light ◽

Efficacy And Safety ◽

Endovenous Laser Ablation ◽

The Past ◽

Early Evidence ◽

Endovenous Treatment

SummaryOver the past ten years endoveous treatment options for varicose veins have evovled considerably, offering clinicians a multitude of options to meet the needs of their patients. The endothermal ablation procedures have moved to the forefront as the choice modality for treating truncal reflux. Both radiofrequency ablation and endovenous laser ablation are widely accepted and interchangeable, showing comparable efficacy and safety. Although numerous endovenous laser wavelengths exist, the data indicates that the differences do not affect the efficacy or postoperative recovery of the procedure. The endovenous laser innovation that has shown early evidence of improved patient outcome is the jacket-tip fiber. The versatility of sclerotherapy makes it a critical component in the endovenous treatment of varicosities. Although not approved by the Food and Drug Administration (USA), the use of a foamed sclerosing agent is the fastest growing segment of sclerotherapy and an important treatment modality in the future of varicose vein treatment. Cutaneous lasers and intense pulse light devices contribute a crucial element, enabling clinicians to treat minute veins that may be impossible to treat with other therapies.

Download Full-text

Provision of Remedies for Violation of Economic, Social and Cultural Rights: A Comparative Study of the United Nations, Inter-American and African Human Rights Systems

African Journal of International and Comparative Law ◽

10.3366/ajicl.2020.0314 ◽

2020 ◽

Vol 28 (2) ◽

pp. 298-318

Author(s):

Roman Girma Teshome

Keyword(s):

Human Rights ◽

United Nations ◽

Comparative Study ◽

Economic Rights ◽

Regional Monitoring ◽

Cultural Rights ◽

The Past ◽

The United Nations ◽

To Receive

The effectiveness of human rights adjudicative procedures partly, if not most importantly, hinges upon the adequacy of the remedies they grant and the implementation of those remedies. This assertion also holds water with regard to the international and regional monitoring bodies established to receive individual complaints related to economic, social and cultural rights (hereinafter ‘ESC rights’ or ‘socio-economic rights’). Remedies can serve two major functions: they are meant, first, to rectify the pecuniary and non-pecuniary damage sustained by the particular victim, and second, to resolve systematic problems existing in the state machinery in order to ensure the non-repetition of the act. Hence, the role of remedies is not confined to correcting the past but also shaping the future by providing reforming measures a state has to undertake. The adequacy of remedies awarded by international and regional human rights bodies is also assessed based on these two benchmarks. The present article examines these issues in relation to individual complaint procedures that deal with the violation of ESC rights, with particular reference to the case laws of the three jurisdictions selected for this work, i.e. the United Nations, Inter-American and African Human Rights Systems.

Download Full-text

Conventional versus Mindfulness-based Interventions for Anxiety and Worry: A Review and Recommendations

Current Psychiatry Research and Reviews ◽

10.2174/2666082216666200220121648 ◽

2020 ◽

Vol 16 (1) ◽

pp. 60-67

Author(s):

Deah Jo Abbott ◽

Caleb Wayne Lack

Keyword(s):

Treatment Options ◽

Additional Treatment ◽

Third Wave ◽

Stage Model ◽

Pharmacological Treatments ◽

The Past ◽

Behavioral Therapies ◽

Cognitive Behavioral Therapies ◽

Specific Disorders ◽

Psychiatric Problems

Anxiety disorders are among the most prevalent and most functionally impairing psychiatric problems experienced by the population. Both pharmacological and psychological evidencebased treatments exist for a number of specific disorders, but may fail to fully relieve symptoms, pointing to the need for additional treatment options. Often considered to be part of the “third wave” of cognitive-behavioral therapies, treatments incorporating mindfulness have emerged in the past two decades as increasingly popular with clinicians and frequently sought out by consumers. The present article reviews the extant literature regarding the efficacy and effectiveness of mindfulnessbased treatments for anxiety, worry, and related problems. Although they have not attained the solid empirical status of CBT or certain pharmacological treatments, the extant research shows mindfulness- based interventions appear to be a promising and useful treatment for people suffering from anxiety and worry. Further work should be done, levels 3-5 of the NIH stage model to determine whether or not they should be further implemented.

Download Full-text

Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer

Journal of Molecular Pathology ◽

10.3390/jmp2030021 ◽

2021 ◽

Vol 2 (3) ◽

pp. 241-254

Author(s):

Pasquale Pisapia ◽

Francesco Pepe ◽

Antonino Iaccarino ◽

Roberta Sgariglia ◽

Mariantonia Nacchio ◽

...

Keyword(s):

Lung Cancer ◽

Liquid Biopsy ◽

Treatment Options ◽

Molecular Testing ◽

Specific Information ◽

Sample Collection ◽

Timely Manner ◽

Oncology Practice ◽

Nsclc Patients ◽

To Receive

Lung cancer is the leading cause of cancer death worldwide. Despite the emergence of highly effective targeted therapies, up to 30% of advanced stage non-small cell lung cancer (NSCLC) patients do not undergo tissue molecular testing because of scarce tissue availability. Liquid biopsy, on the other hand, offers these patients a valuable opportunity to receive the best treatment options in a timely manner. Indeed, besides being much faster and less invasive than conventional tissue-based analysis, it can also yield specific information about the genetic make-up and evolution of patients’ tumors. However, several issues, including lack of standardized protocols for sample collection, processing, and interpretation, still need to be addressed before liquid biopsy can be fully incorporated into routine oncology practice. Here, we reviewed the most important challenges hindering the implementation of liquid biopsy in oncology practice, as well as the great advantages of this approach for the treatment of NSCLC patients.

Download Full-text

Cancer-related fatigue: an overview

British Journal of Nursing ◽

10.12968/bjon.2021.30.4.s36 ◽

2021 ◽

Vol 30 (4) ◽

pp. S36-S43

Author(s):

Mohammed Al Maqbali

Keyword(s):

Negative Impact ◽

Management Strategies ◽

Background Information ◽

Clinical Settings ◽

Measurement Scales ◽

Major Life ◽

Patients With Cancer ◽

Cancer Related Fatigue ◽

Diagnosis Of Cancer ◽

Life Stressor

A diagnosis of cancer is a major life stressor that can affect the physiological, psychological and physical state of the person concerned. Fatigue is a particularly common and troubling symptom that has a negative impact on quality of life throughout all phases of treatment and stages of the illness. The aim of this review is to provide background information on cancer-related fatigue. This review discusses cancer-related fatigue (CRF) in terms of the definition, prevalence, risk factors, aetiology, and the measurement scales used. The differences between definitions of symptoms and relevant theories will be explored and discussed to help explain the variety of instruments used in its measurement. The prevalence of fatigue will be assessed by looking critically at the evidence of fatigue and the factors that affect it. Potential treatment and management strategies for CRF will also be discussed. Finally, there will be an overview of the instruments used to measure fatigue. This review also provides important evidence for measuring and managing CRF that can help nurses to understand fatigue among patients with cancer. Assessing CRF should be routinely undertaken in clinical settings to help identify the proper interventions, treatments and management to reduce fatigue among cancer patients.

Download Full-text